ProKidney Corp. · 10 hours ago
Programming Contractor
ProKidney is a company focused on advancing kidney health, and they are seeking a Programming Contractor to develop programming code using SAS for various statistical outputs. The role involves ensuring quality standards are met, performing validation programming, and maintaining project documentation.
Health CareTherapeutics
Responsibilities
Uses SAS to develop programming code to generate summary tables, data listings, graphs, and derived datasets, SDTM and ADaM, as specified in the statistical analysis plan and programming specifications
Creates SDTM and ADaM mapping specifications and, if required, annotation of case report forms (CRFs) to CDISC standards
Works to ensure that outputs meet quality standards and project requirements
Performs validation programming and works with other Programmers, Biostatisticians, and other project team members to resolve discrepancies or any findings
Keeps project team members informed of programming progress and issues requiring their attention
Follows applicable SOPs, WIs, and relevant regulatory guidelines
Maintains well organized, complete, and up-to-date project documentation, testing, and verification/quality control documents and programs ensuring inspection readiness
Adapts to timeline or priority changes
Reviews project documentation such as Statistical Analysis Plan, mock shells, programming specifications, annotated CRFs, and SAS database design. Provides feedback to the appropriate project team members which reflects forethought and reduces inefficiencies in programming activities
Performs other tasks as assigned
Qualification
Required
10+ years' experience in Pharma, Biotech, or CRO
Strong team player
Applicants must be eligible to work in the United States without the need for work visa or residency sponsorship
Preferred
Preference for Phase 3 and BLA/NDA submission experience
Master's degree preferred (in Statistics, Computer Science, or a related science discipline)
Company
ProKidney Corp.
ProKidney, a pioneer in the treatment of chronic kidney disease through innovations in cellular therapy, was founded in 2015 after a decade of research.
Funding
Current Stage
Public CompanyTotal Funding
$345MKey Investors
Social Capital
2024-06-11Post Ipo Equity· $140M
2022-07-12Post Ipo Equity· $205M
2022-07-12IPO
Recent News
2026-01-06
2026-01-03
Company data provided by crunchbase